DOUBLE-DIGIT EBITDA GROWTH AND FOCUS ON LAUNCHES AND EXECUTION
DOUBLE-DIGIT EBITDA GROWTH AND FOCUS ON LAUNCHES AND EXECUTION
COMPANY ALIGNMENT ON LONG-TERM STRATEGIC AGENDA AND INVESTMENT ON OPERATION
MONTEVIDEO, Uruguay, Nov. 12, 2018 /PRNewswire/ -- Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced today its results for the 3Q18 and 9M18.
HIGHLIGHTS
Net revenues for 3Q18 increased by 2% in constant currency, also impacted by discontinued business and SOLVADI®, marking BRL 829M LTM (including hyperinflation adjustment).
Gross profit rose by 16% vs. 3Q17, in constant currency.
Gross margin of 51% (including hyperinflation adjustments) vs. 50% in 3Q17.
Adjusted EBITDA grew by 34% in constant currency vs. 3Q17.
Adjusted EBITDA margin came to 24% in 3Q18 (including hyperinflation adjustment), improving 283 bps vs. 3Q17.
Net income totaled BRL 13M in 3Q18 (including hyperinflation adjustment) from a loss of BRL 8M in 3Q17.
Adjusted net income up 82% from 3Q17, in constant currency.
Launches of new products continue to be main focus.
Contacts:
Melissa Angelini
ir@grupobiotoscana.com
+55 11 5090-5927
View original content:http://www.prnewswire.com/news-releases/gbt-reports-third-quarter-and-9m18-results-300748842.html
SOURCE Grupo Biotoscana
Company Codes: Luxembourg:BIO
